Hsu et al. discovered that GLUT5 is involved in tumor growth via modulation of glucose metabolism in breast cancer cells, and that GLUT5-targeted BSA nanoparticles significantly enhance drug delivery and anti-tumor efficacy 140. The gene discussed is SLC2A5; the disease is breast carcinoma.